問卷

TPIDB > Search Result

Search Result

篩選

List

248Cases

2024-03-01 - 2026-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus
  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2020-11-30 - 2021-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2016-04-01 - 2021-12-01

Phase I

A Phase 1 ,Randomized, Double-blind,Placebo-controlled Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of Topical BB-101(rhNEGF) for the Treatment of Diabetic Lower Leg and Foot Ulcers
  • Condition/Disease

    Treatment of Diabetic Lower Leg and Foot Ulcers

  • Test Drug

    BB-101

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2020-02-28 - 2022-12-31

Phase II

A Phase 2, open-label study of orally administered PAX-1 therapy in patients with brain metastases secondary to non-small cell lung cancer
  • Condition/Disease

    Brain metastases secondary to non-small cell lung cancer

  • Test Drug

    PAX-1

Participate Sites
8Sites

Recruiting8Sites

2021-12-01 - 2022-12-01

Phase II

A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 versus Placebo in Gout Patients
  • Condition/Disease

    Gout

  • Test Drug

    AR882

Participate Sites
5Sites

Recruiting5Sites

2021-12-01 - 2023-04-07

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-11-19 - 2022-12-01

Phase III

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Test Drug

    dapagliflozin film-coated tablets

Participate Sites
15Sites

Recruiting13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases